Metabolic effect of PGE 1 analogue 01206.αCD on nerve Na +-K +-ATPase activity of rats with streptozocin-induced diabetes is mediated via cAMP: Possible role of cAMP in diabetic neuropathy

Abstract

We investigated the dose-dependent effects of prostaglandin E 1 (PGE 1) analogue, OP1206.αCD (OP), on motor nerve conduction velocity (MNCV), nerve blood flow (NBF) and Na +-K +-ATPase (ATPase) activity in streptozocin-induced diabetic rats. At 10 μg/kg/day, OP ameliorated MNCV and NBF, but no ATPase activity, whereas at 30 μg/kg/day it increased MNCV and ATPase activity, but not NBF. These results suggested a possible direct metabolic effect of OP, at least at a certain dose, on ATPase activity independent of NBF. Since PGE 1 exerts an effect on nerve cAMP content, we conducted an in vitro study to clarify the relationship of cAMP to the modulation of ATPase activity in diabetic nerves. We studied sciatic nerves isolated from 53 rats with streptozocin-induced diabetes that had exhibited hyperglycemia for 6 wk. OP increased the activity of ATPase and the accumulation of cAMP in a dose-dependent manner. Dibutyryl cAMP, a cAMP analogue, and aminophylline, which increases nerve cAMP content, enhanced ATPase activity in a dose-dependent manner. In addition, the increased activity of ATPase in diabetic nerves produced by OP was suppressed by a protein kinase inhibitor, H8. These results suggest that ATPase activity in diabetic nerves might be regulated or modified by cAMP and, possibly, by protein kinase A, a finding that is important for clarifying the pathogenesis of diabetic neuropathy and for developing new approaches to treatment.